![]() |
|
|
Vol. 300, Issue 2, 621-628, February 2002
Unité de Neurobiologie et Pharmacologie Moléculaire
(U109) de l'Institut National de la Santé et de la Recherche
Médicale, Centre Paul Broca, Paris, France (S.M., C.P., J.T.-L.,
D.W., P.S., J.-C.S., J.-M.A.); and Imagerie Cellulaire des
Neurorécepteurs et Physiopathologie Neuroendocrinienne,
Hôpital Saint-Antoine, Paris, France (W.R., C.B.)
We have explored the role of endogenous dopamine in the control of
histaminergic neuron activity in mouse brain regions evaluated by
changes in tele-methylhistamine (t-MeHA) levels. In
vitro, methamphetamine released [3H]noradrenaline but
failed to release [3H]histamine from synaptosomes. In
vivo, methamphetamine enhanced t-MeHA levels by about 2-fold with
ED50 values of ~1 mg/kg in caudate putamen, nucleus
accumbens, cerebral cortex, and hypothalamus. This response selectively
involved the D2 and not the D3 receptor as
indicated by its blockade by haloperidol and by its persistence after
administration of nafadotride, a D3 receptor preferential ligand, or in (
/
) D3 receptor-deficient mice. The
t-MeHA response to methamphetamine was delayed compared with the
locomotor-activating effect of this drug, suggesting that it is of
compensatory nature. In agreement, ciproxifan, an inverse agonist known
to enhance histamine neuron activity, decreased the hyperlocomotion
induced by methamphetamine. Repeated methamphetamine administration
resulted in the expected sensitization to the hyperlocomotor effect of the drug but did not modify either the ED50 or the
Emax regarding t-MeHA levels. However, it
resulted in an enhanced basal t-MeHA level (+30-40%), which was
sustained for at least 11 days after withdrawal in hypothalamus,
striatum, and cerebral cortex and suppressed by haloperidol. Hence,
both the acute and chronic administration of methamphetamine enhance
histamine neuron activity, presumably in a compensatory manner.
Repeated methamphetamine administration also resulted in a modified
balance in the opposite influences of dopamine and serotonin on
histaminergic neurons as revealed by the enhanced response to
haloperidol and abolished response to ketanserin, respectively.
This article has been cited by other articles:
![]() |
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Esbenshade, G. B. Fox, and M. D. Cowart Histamine h3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv., April 1, 2006; 6(2): 77 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pillot, J. Ortiz, A. Heron, S. Ridray, J.-C. Schwartz, and J.-M. Arrang Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat J. Neurosci., August 15, 2002; 22(16): 7272 - 7280. [Abstract] [Full Text] [PDF] |
||||